Evogene Ltd.
corporate_fare Company Profile
Evogene Ltd. (NASDAQ:EVGN) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 40 items for EVGN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for EVGN spans 6-K, SCHEDULE 13D/A, 4, SCHEDULE 13D.
Recent high-impact activity:
- Evogene Q3 Revenue Collapses to $141K After Bayer Deal Ends, Loss Widens
- Evogene Chairman Nir Nimrodi Resigns Board Seat
- Evogene and Activist Pure Capital Reach Deal to End Proxy Fight, Reconstitute Board
- Evogene Secures 180-Day Nasdaq Extension to Regain $1 Bid Compliance
- Evogene Reports H1 2026 Loss, Fully Utilizes ATM, and Faces Nasdaq Deadline and Dissident Tender Offer
Financial Snapshot
Short Interest & Short Volume
2.33 days to coverFINRA reported short interest of 70,324 shares in EVGN as of the October 30, 2026 settlement, a 10.1% increase from the prior period — about 2.3 days to cover at its recent average daily volume. On November 20, 2026, 40.3% of EVGN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for EVGN, detected from its recent SEC filings · based on capital-structure filings through 2026-07-17.
ATM Upsized to $3.3M · $1.75M Already Sold
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
EVGN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.